 |
|
|
| |
Incidence and predictors of flares after discontinuing nucleos(t)ide analogue
therapy in HBeAg negative patients with chronic hepatitis B: Results from the randomized controlled STOP Study
|
| |
| |
Reported by Jules Levin
EASL 2019 April 10-4 Vienna
The study was sponsored by the Toronto Centre for Liver Disease, Toronto, Canada. Financial support was provided by Gilead Sciences Inc., Foster City, USA. The funding source did not have any influence on study design, data collection, analysis and interpretation of the data, writing of the report nor the decision to submit for publication
|
| |
|
|
|
|
|
